These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 39348274

  • 1. Association between triglyceride glucose-body mass index and the staging of non-alcoholic steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease.
    Zhang F, Han Y, Wu Y, Bao Z, Zheng G, Liu J, Li W.
    Ann Med; 2024 Dec; 56(1):2409342. PubMed ID: 39348274
    [Abstract] [Full Text] [Related]

  • 2. PERFORMACE OF TRIGLYCERIDE-GLUCOSE INDEX ON DIAGNOSIS AND STAGING OF NAFLD IN OBESE PATIENTS.
    Smiderle CA, Coral GP, DE Carli LA, Mattos AA, Mattos AZ, Tovo CV.
    Arq Gastroenterol; 2021 Dec; 58(2):139-144. PubMed ID: 34231659
    [Abstract] [Full Text] [Related]

  • 3. The triglyceride-glucose index is associated with the severity of hepatic steatosis and the presence of liver fibrosis in non-alcoholic fatty liver disease: a cross-sectional study in Chinese adults.
    Guo W, Lu J, Qin P, Li X, Zhu W, Wu J, Xu N, Zhang Q.
    Lipids Health Dis; 2020 Oct 07; 19(1):218. PubMed ID: 33028338
    [Abstract] [Full Text] [Related]

  • 4. [Triglyceride-glucose index in non-obese individuals: its association with and predictive value for non-alcoholic fatty liver disease].
    Xiao J, Li Y, Fang M, Gong H, Li W, Zhang C, Chen F, Zhang Y, Han T.
    Nan Fang Yi Ke Da Xue Xue Bao; 2024 Jul 20; 44(7):1266-1271. PubMed ID: 39051072
    [Abstract] [Full Text] [Related]

  • 5. Association between triglyceride glucose-body mass index and non-alcoholic fatty liver disease in the non-obese Chinese population with normal blood lipid levels: a secondary analysis based on a prospective cohort study.
    Li Y, Zheng R, Li J, Feng S, Wang L, Huang Z.
    Lipids Health Dis; 2020 Oct 28; 19(1):229. PubMed ID: 33109219
    [Abstract] [Full Text] [Related]

  • 6. A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study.
    Harrison SA, Ratziu V, Boursier J, Francque S, Bedossa P, Majd Z, Cordonnier G, Sudrik FB, Darteil R, Liebe R, Magnanensi J, Hajji Y, Brozek J, Roudot A, Staels B, Hum DW, Megnien SJ, Hosmane S, Dam N, Chaumat P, Hanf R, Anstee QM, Sanyal AJ.
    Lancet Gastroenterol Hepatol; 2020 Nov 28; 5(11):970-985. PubMed ID: 32763196
    [Abstract] [Full Text] [Related]

  • 7. Triglyceride Glucose Index and Related Parameters (Triglyceride Glucose-Body Mass Index and Triglyceride Glucose-Waist Circumference) Identify Nonalcoholic Fatty Liver and Liver Fibrosis in Individuals with Overweight/Obesity.
    Khamseh ME, Malek M, Abbasi R, Taheri H, Lahouti M, Alaei-Shahmiri F.
    Metab Syndr Relat Disord; 2021 Apr 28; 19(3):167-173. PubMed ID: 33259744
    [Abstract] [Full Text] [Related]

  • 8. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
    Rastogi A, Shasthry SM, Agarwal A, Bihari C, Jain P, Jindal A, Sarin S.
    APMIS; 2017 Nov 28; 125(11):962-973. PubMed ID: 29076589
    [Abstract] [Full Text] [Related]

  • 9. The usefulness of obesity and lipid-related indices to predict the presence of Non-alcoholic fatty liver disease.
    Sheng G, Lu S, Xie Q, Peng N, Kuang M, Zou Y.
    Lipids Health Dis; 2021 Oct 10; 20(1):134. PubMed ID: 34629059
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity.
    Di Mauro S, Scamporrino A, Petta S, Urbano F, Filippello A, Ragusa M, Di Martino MT, Scionti F, Grimaudo S, Pipitone RM, Privitera G, Di Pino A, Scicali R, Valenti L, Dongiovanni P, Fracanzani A, Rabuazzo AM, Craxì A, Purrello M, Purrello F, Piro S.
    Liver Int; 2019 Sep 10; 39(9):1742-1754. PubMed ID: 31169972
    [Abstract] [Full Text] [Related]

  • 12. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease.
    Nascimbeni F, Bedossa P, Fedchuk L, Pais R, Charlotte F, Lebray P, Poynard T, Ratziu V, LIDO (Liver Injury in Diabetes and Obesity) Study Group.
    J Hepatol; 2020 May 10; 72(5):828-838. PubMed ID: 31862486
    [Abstract] [Full Text] [Related]

  • 13. The triglyceride glucose-body mass index: a non-invasive index that identifies non-alcoholic fatty liver disease in the general Japanese population.
    Hu H, Han Y, Cao C, He Y.
    J Transl Med; 2022 Sep 05; 20(1):398. PubMed ID: 36064712
    [Abstract] [Full Text] [Related]

  • 14. The triglycerides and glucose (TyG) index: A new marker associated with nonalcoholic steatohepatitis (NASH) in obese patients.
    Rivière B, Jaussent A, Macioce V, Faure S, Builles N, Lefebvre P, Géraud P, Picot MC, Rebuffat S, Renard E, Paradis V, Servais MD, de Preville N, Nocca D, Lajoix AD, Pageaux GP, Galtier F, COMET study group.
    Diabetes Metab; 2022 Jul 05; 48(4):101345. PubMed ID: 35339664
    [Abstract] [Full Text] [Related]

  • 15.  The product of triglycerides and glucose as biomarker for screening simple steatosis and NASH in asymptomatic women.
    Simental-Mendía LE, Simental-Mendía E, Rodríguez-Hernández H, Rodríguez-Morán M, Guerrero-Romero F.
    Ann Hepatol; 2016 Jul 05; 15(5):715-20. PubMed ID: 27493110
    [Abstract] [Full Text] [Related]

  • 16. Association between triglyceride-glucose related indices and mortality among individuals with non-alcoholic fatty liver disease or metabolic dysfunction-associated steatotic liver disease.
    Chen Q, Hu P, Hou X, Sun Y, Jiao M, Peng L, Dai Z, Yin X, Liu R, Li Y, Zhu C.
    Cardiovasc Diabetol; 2024 Jul 04; 23(1):232. PubMed ID: 38965572
    [Abstract] [Full Text] [Related]

  • 17. Triglyceride Glucose Index is Associated with Ultrasonographic Fatty Liver Indicator in Children and Adolescents with Non-alcoholic Fatty Liver Disease.
    Kim B, Jin HY, Yoon JS, Noh ES, Hwang IT.
    J Clin Res Pediatr Endocrinol; 2024 Sep 05; 16(3):306-313. PubMed ID: 38664989
    [Abstract] [Full Text] [Related]

  • 18. ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD.
    Corey KE, Pitts R, Lai M, Loureiro J, Masia R, Osganian SA, Gustafson JL, Hutter MM, Gee DW, Meireles OR, Witkowski ER, Richards SM, Jacob J, Finkel N, Ngo D, Wang TJ, Gerszten RE, Ukomadu C, Jennings LL.
    J Hepatol; 2022 Jan 05; 76(1):25-33. PubMed ID: 34600973
    [Abstract] [Full Text] [Related]

  • 19. Usefulness of the triglyceride glucose-body mass index in evaluating nonalcoholic fatty liver disease: insights from a general population.
    Wang R, Dai L, Zhong Y, Xie G.
    Lipids Health Dis; 2021 Jul 28; 20(1):77. PubMed ID: 34321005
    [Abstract] [Full Text] [Related]

  • 20. Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease.
    Jiang ZG, Tapper EB, Connelly MA, Pimentel CF, Feldbrügge L, Kim M, Krawczyk S, Afdhal N, Robson SC, Herman MA, Otvos JD, Mukamal KJ, Lai M.
    Liver Int; 2016 Aug 28; 36(8):1213-20. PubMed ID: 26815314
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.